The Chemokine Receptor CCR1 Is Constitutively Active, Which Leads to G Protein-independent, β-Arrestin-mediated Internalization*

Background: CCR1 is a chemokine receptor of significant importance in human health, yet little is known about its ligand-independent behavior. Results: CCR1 exhibits constitutive activity leading to basal signaling and β-arrestin-mediated receptor internalization. Conclusion: Constitutive activity may enable CCR1 to engage in dual functions of canonical signaling and non-canonical chemokine scavenging. Significance: This may suggest a new function for CCR1 and avenue for drug development. Activation of G protein-coupled receptors by their associated ligands has been extensively studied, and increasing structural information about the molecular mechanisms underlying ligand-dependent receptor activation is beginning to emerge with the recent expansion in GPCR crystal structures. However, some GPCRs are also able to adopt active conformations in the absence of agonist binding that result in the initiation of signal transduction and receptor down-modulation. In this report, we show that the CC-type chemokine receptor 1 (CCR1) exhibits significant constitutive activity leading to a variety of cellular responses. CCR1 expression is sufficient to induce inhibition of cAMP formation, increased F-actin content, and basal migration of human and murine leukocytes. The constitutive activity leads to basal phosphorylation of the receptor, recruitment of β-arrestin-2, and subsequent receptor internalization. CCR1 concurrently engages Gαi and β-arrestin-2 in a multiprotein complex, which may be accommodated by homo-oligomerization or receptor clustering. The data suggest the presence of two functional states for CCR1; whereas receptor coupled to Gαi functions as a canonical GPCR, albeit with high constitutive activity, the CCR1·β-arrestin-2 complex is required for G protein-independent constitutive receptor internalization. The pertussis toxin-insensitive uptake of chemokine by the receptor suggests that the CCR1·β-arrestin-2 complex may be related to a potential scavenging function of the receptor, which may be important for maintenance of chemokine gradients and receptor responsiveness in complex fields of chemokines during inflammation.

[1]  E. Borroni,et al.  Review: Structure-function and biological properties of the atypical chemokine receptor D6. , 2013, Molecular immunology.

[2]  A. Mantovani,et al.  β-Arrestin–Dependent Activation of the Cofilin Pathway Is Required for the Scavenging Activity of the Atypical Chemokine Receptor D6 , 2013, Science Signaling.

[3]  C. Martínez-A,et al.  Chemokine receptor oligomerization: a further step toward chemokine function. , 2012, Immunology letters.

[4]  D. Hall,et al.  Development of operational models of receptor activation including constitutive receptor activity and their use to determine the efficacy of the chemokine CCL17 at the CC chemokine receptor CCR4 , 2012, British journal of pharmacology.

[5]  E. Cameroni,et al.  CCR2 Acts as Scavenger for CCL2 during Monocyte Chemotaxis , 2012, PloS one.

[6]  R. Leurs,et al.  Pharmacological modulation of chemokine receptor function , 2012, British journal of pharmacology.

[7]  M. Halls.  Constitutive formation of an RXFP1‐signalosome: a novel paradigm in GPCR function and regulation , 2012, British journal of pharmacology.

[8]  Jean Martinez,et al.  High Constitutive Activity Is an Intrinsic Feature of Ghrelin Receptor Protein , 2011, The Journal of Biological Chemistry.

[9]  J. Fox,et al.  Mechanisms regulating chemokine receptor activity , 2011, Immunology.

[10]  T. Handel,et al.  A rapid and efficient way to obtain modified chemokines for functional and biophysical studies. , 2011, Cytokine.

[11]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[12]  T. Sakmar,et al.  CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration* , 2011, The Journal of Biological Chemistry.

[13]  P. Tak,et al.  Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis , 2011, PloS one.

[14]  T. Schall,et al.  Overcoming hurdles in developing successful drugs targeting chemokine receptors , 2011, Nature Reviews Immunology.

[15]  W. Hubbell,et al.  Few Residues within an Extensive Binding Interface Drive Receptor Interaction and Determine the Specificity of Arrestin Proteins* , 2011, The Journal of Biological Chemistry.

[16]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[17]  R. Gladue,et al.  CCR1 antagonists: what have we learned from clinical trials. , 2010, Current topics in medicinal chemistry.

[18]  D. Cooper,et al.  Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, β-arrestin 2, PDE4D3 complex , 2010, The EMBO journal.

[19]  K. Matsushima,et al.  Deficiency of Chemokine Receptor CCR1 Causes Osteopenia Due to Impaired Functions of Osteoclasts and Osteoblasts* , 2010, The Journal of Biological Chemistry.

[20]  G. Luker,et al.  Constitutive and Chemokine-dependent Internalization and Recycling of CXCR7 in Breast Cancer Cells to Degrade Chemokine Ligands , 2010, Oncogene.

[21]  G. Haegeman,et al.  KLHL12-mediated ubiquitination of the dopamine D4 receptor does not target the receptor for degradation. , 2010, Cellular signalling.

[22]  G. Haegeman,et al.  Resistance of the dopamine D4 receptor to agonist-induced internalization and degradation. , 2010, Cellular signalling.

[23]  T. Benned-Jensen,et al.  Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants , 2010, British journal of pharmacology.

[24]  B. Ranchin,et al.  The Constitutively Active V2 Receptor Mutants Conferring NSIAD Are Weakly Sensitive to Agonist and Antagonist Regulation , 2009, PloS one.

[25]  P. Tak,et al.  MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. , 2009, Arthritis and rheumatism.

[26]  T. Handel,et al.  Expression, purification and in vitro functional reconstitution of the chemokine receptor CCR1. , 2009, Protein expression and purification.

[27]  F. Baleux,et al.  CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. , 2009, Blood.

[28]  K. Eidne,et al.  Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis. , 2009, Molecular endocrinology.

[29]  K. Eidne,et al.  Agonist-Independent Interactions between β-Arrestins and Mutant Vasopressin Type II Receptors Associated with Nephrogenic Syndrome of Inappropriate Antidiuresis , 2009 .

[30]  Roland Seifert,et al.  High constitutive activity and a G-protein-independent high-affinity state of the human histamine H(4)-receptor. , 2009, Biochemistry.

[31]  Ya-Xiong Tao,et al.  Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. , 2008, Pharmacology & therapeutics.

[32]  M. Rosenkilde,et al.  Structural Motifs of Importance for the Constitutive Activity of the Orphan 7TM Receptor EBI2: Analysis of Receptor Activation in the Absence of an Agonist , 2008, Molecular Pharmacology.

[33]  Jens V Stein,et al.  How chemokines invite leukocytes to dance , 2008, Nature Immunology.

[34]  Arun K Shukla,et al.  Distinct conformational changes in β-arrestin report biased agonism at seven-transmembrane receptors , 2008, Proceedings of the National Academy of Sciences.

[35]  R. Ransohoff,et al.  Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. , 2008, Blood.

[36]  R. Seifert,et al.  Functional reconstitution of the human chemokine receptor CXCR4 with Gi/Go-proteins in Sf9 insect cells , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[37]  Vsevolod V Gurevich,et al.  How and why do GPCRs dimerize? , 2008, Trends in pharmacological sciences.

[38]  Cyril Couturier,et al.  The BRET technology and its application to screening assays , 2008, Biotechnology journal.

[39]  V. Gurevich,et al.  GPCR monomers and oligomers: it takes all kinds , 2008, Trends in Neurosciences.

[40]  Pascale G. Charest,et al.  Unraveling G Protein-coupled Receptor Endocytosis Pathways Using Real-time Monitoring of Agonist-promoted Interaction between β-Arrestins and AP-2* , 2007, Journal of Biological Chemistry.

[41]  S. Mundell,et al.  The calcium-sensing receptor changes cell shape via a β-arrestin-1–ARNO–ARF6–ELMO protein network , 2007, Journal of Cell Science.

[42]  T. Schwartz,et al.  Molecular Interaction of a Potent Nonpeptide Agonist with the Chemokine Receptor CCR8 , 2007, Molecular Pharmacology.

[43]  L. Pardo,et al.  The activation mechanism of chemokine receptor CCR5 involves common structural changes but a different network of interhelical interactions relative to rhodopsin. , 2007, Cellular signalling.

[44]  Andrea Iaboni,et al.  A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer , 2006, Nature Methods.

[45]  A. Gruber,et al.  Deletion of CCR1 Attenuates Pathophysiologic Responses during Respiratory Syncytial Virus Infection , 2006, Journal of Immunology.

[46]  F. Hamdan,et al.  Monitoring Protein‐Protein Interactions in Living Cells by Bioluminescence Resonance Energy Transfer (BRET) , 2006, Current protocols in neuroscience.

[47]  T. Kenakin.  The physiological significance of constitutive receptor activity , 2005 .

[48]  R. Horuk,et al.  BX471: a CCR1 antagonist with anti-inflammatory activity in man. , 2005, Mini reviews in medicinal chemistry.

[49]  H. Anders,et al.  Chemokine Receptor CCR1: A New Target for Progressive Kidney Disease , 2005, American Journal of Nephrology.

[50]  M. Parmentier,et al.  Mutation of the DRY Motif Reveals Different Structural Requirements for the CC Chemokine Receptor 5-Mediated Signaling and Receptor Endocytosis , 2005, Molecular Pharmacology.

[51]  Michel Bouvier,et al.  Real-time monitoring of receptor and G-protein interactions in living cells , 2005, Nature Methods.

[52]  M. Kretzler,et al.  CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. , 2004, Kidney international.

[53]  B. Conklin,et al.  Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. , 2004, The Journal of clinical investigation.

[54]  H. Sung,et al.  Differential effects of 9-cis retinoic acid on expression of CC chemokine receptors in human monocytes. , 2004, Biochemical pharmacology.

[55]  Alberto Mantovani,et al.  β-Arrestin-dependent Constitutive Internalization of the Human Chemokine Decoy Receptor D6* , 2004, Journal of Biological Chemistry.

[56]  R. Lefkowitz,et al.  Multifaceted roles of β-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling , 2003 .

[57]  J. Broach,et al.  Constitutive Activation of CCR5 and CCR2 Induced by Conformational Changes in the Conserved TXP Motif in Transmembrane Helix 2* , 2003, Journal of Biological Chemistry.

[58]  R. Lefkowitz,et al.  G-protein-coupled Receptor (GPCR) Kinase Phosphorylation and β-Arrestin Recruitment Regulate the Constitutive Signaling Activity of the Human Cytomegalovirus US28 GPCR* , 2003, Journal of Biological Chemistry.

[59]  A. Satoskar,et al.  CC chemokine receptor 1 enhances susceptibility to Leishmania major during early phase of infection , 2003, Immunology and cell biology.

[60]  Y. Wan,et al.  Identification of full, partial and inverse CC chemokine receptor 3 agonists using [35S]GTPgammaS binding. , 2002, European journal of pharmacology.

[61]  Martin A. Schwarz,et al.  Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL‐60 cells: antagonism of hCCR1 activation by MIP‐1β , 2002, British journal of pharmacology.

[62]  Roland Contreras,et al.  Structure and function in rhodopsin: High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[63]  P. Corvol,et al.  Lessons from constitutively active mutants of G protein-coupled receptors , 2002, Trends in Endocrinology & Metabolism.

[64]  R. Seifert,et al.  Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[65]  H. Betz,et al.  G-protein-coupled receptors for neurotransmitter amino acids: C-terminal tails, crowded signalosomes. , 2002, The Biochemical journal.

[66]  J. Broach,et al.  A Point Mutation That Confers Constitutive Activity to CXCR4 Reveals That T140 Is an Inverse Agonist and That AMD3100 and ALX40-4C Are Weak Partial Agonists* , 2002, The Journal of Biological Chemistry.

[67]  P. Loetscher,et al.  Homing chemokines in rheumatoid arthritis , 2002, Arthritis research.

[68]  S. Kunkel,et al.  Chemokines in autoimmune disease. , 2001, Current opinion in immunology.

[69]  M. Mack,et al.  Cellular Assays of Chemokine Receptor Activation , 2001, Current protocols in pharmacology.

[70]  R. Horuk,et al.  CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. , 2001, Immunology letters.

[71]  S. Ferguson,et al.  Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.

[72]  C. Weber,et al.  A Non-peptide Functional Antagonist of the CCR1 Chemokine Receptor Is Effective in Rat Heart Transplant Rejection* , 2001, The Journal of Biological Chemistry.

[73]  M. Caron,et al.  Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  M. Ascoli,et al.  Effect of activating and inactivating mutations on the phosphorylation and trafficking of the human lutropin/choriogonadotropin receptor. , 2000, Molecular endocrinology.

[75]  A. IJzerman,et al.  Inverse agonism at G protein‐coupled receptors: (patho)physiological relevance and implications for drug discovery , 2000, British journal of pharmacology.

[76]  D R Flower,et al.  Modelling G-protein-coupled receptors for drug design. , 1999, Biochimica et biophysica acta.

[77]  J. Burger,et al.  Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. , 1999, Journal of immunology.

[78]  C. Martínez-A,et al.  The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[79]  M. Oppermann,et al.  Chemokine‐induced phosphorylation of CC chemokine receptor 5 (CCR5) , 1999, Journal of leukocyte biology.

[80]  C. Browning,et al.  Signalling by CXC‐chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPγS binding induced by IL‐8 and GROα , 1999, British journal of pharmacology.

[81]  J. Boyd,et al.  Identification of C-c Chemokine Receptor 1 (ccr1) as the Monocyte Hemofiltrate C-c Chemokine (hcc)-1 Receptor , 1998 .

[82]  I. Charo,et al.  Chemotaxis in a lymphocyte cell line transfected with C-C chemokine receptor 2B: Evidence that directed migration is mediated by βγ dimers released by activation of Gαi-coupled receptors , 1997 .

[83]  L. Steinman,et al.  Perivascular T Cells Express the Pro‐Inflammatory Chemokine RANTES mRNA in Multiple Sclerosis Lesions , 1997, Scandinavian journal of immunology.

[84]  Jean Salamero,et al.  HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.

[85]  H. Broxmeyer,et al.  Impaired Host Defense, Hematopoiesis, Granulomatous Inflammation and Type 1–Type 2 Cytokine Balance in Mice Lacking CC Chemokine Receptor 1 , 1997, The Journal of experimental medicine.

[86]  S. Coughlin,et al.  Phosphorylation by a G protein-coupled kinase inhibits signaling and promotes internalization of the monocyte chemoattractant protein-1 receptor. Critical role of carboxyl-tail serines/threonines in receptor function. , 1996, Journal of immunology.

[87]  R. Strieter,et al.  An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. , 1995, Journal of immunology.

[88]  R. Lefkowitz,et al.  A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[89]  A Herz,et al.  Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[90]  A. Ashkenazi,et al.  Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes , 1988, Nature.

[91]  T. Handel,et al.  Chemokine receptor oligomerization and allostery. , 2013, Progress in molecular biology and translational science.

[92]  E. Borroni,et al.  Dissecting trafficking and signaling of atypical chemokine receptors. , 2013, Methods in enzymology.

[93]  J. Shaw,et al.  Chemokine blockers--therapeutics in the making? , 2006, Trends in pharmacological sciences.

[94]  W. Hancock,et al.  Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. , 2000, The Journal of clinical investigation.

[95]  J. Benovic,et al.  Regulation of G protein-coupled receptors by receptor kinases and arrestins. , 1995, Vitamins and hormones.